A Phase 3 interventional study of Deucravacitinib and Placebo in Psoriatic Arthritis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 138 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 3 of them phase 3. Arthritis, Psoriatic · Bristol-Myers Squibb.
Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, this one is one of 2 that started in 2021, is one of 4 in phase 3, and was the 8th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →1 of the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb is open now. Recruiting first, the newest first:
Bristol-Myers Squibb
Ages 4–75
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 729 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 203 across the 9 interventional studies, 38,396 across the 3 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and efficacy information.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Deucravacitinib
Drug: Deucravacitinib · Other: Placebo
Drug: Apremilast
Specified dose on specified days
Also known as: BMS-986165
Specified dose on specified days
Specified dose on specified days
Also known as: Otezla
Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16
The American College of Rheumatology (ACR) 20 is defined as 20% improvement over baseline in tender (68) and swollen (66) joint counts and a 20% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
Time frame: Week 16
Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.
Time frame: Baseline, Week 16
Change From Baseline in Health Assessment Quiestionnaire - Disability Index (HAQ-DI) at Week 16
HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.
Time frame: Baseline, Week 16
Number of Participants Meeting Psoriasis Area and Severity Index 75 (PASI 75) at Week 16
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
Time frame: Week 16
Change From Baseline in the 36-item Short Form (SF-36) Physical Component Summary (PCS) Score at Week 16
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.
Time frame: Baseline, Week 16
Number of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16
Number of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.
Time frame: Week 16
Number of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16
Number participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count ≤ 1 2. Swollen joint count ≤ 1 3. Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain ≤ 15 5. Patient Global Assessment of PsA disease activity ≤ 20 6. HAQ-DI ≤ 0.5 7. Tender enthesial points ≤ 1
Time frame: Week 16
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16
FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.
Time frame: Baseline, Week 16
Number of Participants Meeting Dactylitis Resolution at Week 16
Number of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count ≥ 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.
Time frame: Week 16
Number of Participants Meeting American College of Rheumatology (ACR) 50 at Week 16
The American College of Rheumatology (ACR) 50 is defined as 50% improvement over baseline in tender (68) and swollen (66) joint counts and a 50% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
Time frame: Week 16
Number of Participants Meeting American College of Rheumatology (ACR) 70 at Week 16
The American College of Rheumatology (ACR) 70 is defined as 70% improvement over baseline in tender (68) and swollen (66) joint counts and a 70% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
Time frame: Week 16
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI)
HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16
Number of Participants Who Achieve a Clinically Meaningful Improvement in HAQ-DI Score at Week 16
Number of participants who achieve a clinically meaningful improvement (≥ 0.35 improvement from baseline) in HAQ-DI score among participants with a HAQ-DI score ≥ 0.35 at baseline. HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered.
Time frame: Week 16
Number of Participants Meeting Psoriasis Area and Severity Index 75 (PASI 75)
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
Time frame: Weeks 4, 8, 12, 16
Number of Participants Meeting Psoriasis Area and Severity Index 90 (PASI 90)
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
Time frame: Weeks 4, 8, 12, 16
Number of Participants Meeting Psoriasis Area and Severity Index 100 (PASI 100)
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
Time frame: Weeks 4, 8, 12, 16
Change From Baseline in the 36-item Short Form (SF-36) Physical Component Summary (PCS) Score
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.
Time frame: Baseline, Weeks 4, 12, 16
Number of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI)
Number of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.
Time frame: Weeks 4, 8, 12, 16
Number of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Spondyloarthritis Research Consortium of Canada (SPARCC)
Number of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by SPARCC. The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (right \[R\]/left \[L\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.
Time frame: Weeks 4, 8, 12, 16
Number of Participants Meeting Achievement of Minimal Disease Activity (MDA)
Number participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count ≤ 1 2. Swollen joint count ≤ 1 3. Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain ≤ 15 5. Patient Global Assessment of PsA disease activity ≤ 20 6. HAQ-DI ≤ 0.5 7. Tender enthesial points ≤ 1
Time frame: Weeks 4, 8, 12, 16
Change From Baseline in the 36-item Short Form (SF-36) Mental Component Summary (MCS) Score
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. The MCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 MCS indicates an improvement.
Time frame: Baseline, Weeks 4, 12, 16
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score
FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16
Number of Participants Meeting Dactylitis Resolution
Number of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count ≥ 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.
Time frame: Weeks 4, 8, 12, 16
Change From Baseline in Psoriatic Arthritis Impact of Disease (PsAID) 12 Score
The Psoriatic Arthritis Impact of Disease (PsAID) is a 12-item self-report that measures PsA symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale with a 1-week recall period. The PsAID has a total score, with a higher value indicating worse health. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in PsAID indicates an improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16
Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAPSA indicates an improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16
Number of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Low Disease Activity Response
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.
Time frame: Weeks 2, 4, 8, 12, 16
Number of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Disease Remission
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.
Time frame: Weeks 2, 4, 8, 12, 16
Number of Participants Meeting Achievement of Physician Global Assessment-Fingernails (PGA-F) of 0/1
The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe.
Time frame: Weeks 4, 8, 12, 16
Change From Baseline in Disease Activity Score (DAS) 28 C-reactive Protein (CRP) Score
The DAS28-CRP is a composite outcome measure that assesses: 1) How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; 2) CRP in the blood to measure the degree of inflammation; 3) Participant Global Assessment of Disease Activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission, 2.6 to 3.2: Low disease activity, 3.2 to 5.1: Moderate disease activity, \> 5.1: High disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16
Number of Participants With Achievement of Disease Activity Score (DAS) 28 C-reactive Protein (CRP) Low Disease Activity Response
The DAS28-CRP is a composite outcome measure that assesses: 1) How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; 2) CRP in the blood to measure the degree of inflammation; 3) Participant Global Assessment of Disease Activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission, 2.6 to 3.2: Low disease activity, 3.2 to 5.1: Moderate disease activity, \> 5.1: High disease activity.
Time frame: Weeks 2, 4, 8, 12, 16
Number of Participants With Achievement of Disease Activity Score (DAS) 28 C-reactive Protein (CRP) Disease Remission
The DAS28-CRP is a composite outcome measure that assesses: 1) How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; 2) CRP in the blood to measure the degree of inflammation; 3) Participant Global Assessment of Disease Activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission, 2.6 to 3.2: Low disease activity, 3.2 to 5.1: Moderate disease activity, \> 5.1: High disease activity.
Time frame: Weeks 2, 4, 8, 12, 16
Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS)
The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite measure calculated from the Physician Global Assessment of PsA, the Participant Global Assessment of Disease Activity, the Short Form-36 PCS, the swollen joint count, the tender joint count, the Enthesitis (LEI), the Dactylitis (LDI) (Basic), and the High-sensitivity C-reactive protein (hsCRP). The range of PASDAS is 0-10. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Time frame: Baseline, Weeks 4, 12, 16
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI)
Four domains are used to calculate the modified Composite Psoriatic Disease Activity Index (mCPDAI): joints (66 swollen joint count and 68 tender joint count; Health Assessment Questionnaire), skin (PASI and DLQI), dactylitis (a simple count of each digit involved), and enthesitis (number of tendons/fascia insertion sites showing enthesitis scored from 0 to 4, based on palpation of Achilles tendon and bilateral plantar fasciae insertion). The mCPDAI is scored using a 4 point scale from 0 (no disease activity) to 3 (most severe disease activity), giving an mCPDAI score range of 0 through 12. A higher score indicates more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Time frame: Baseline, Weeks 4, 8, 12, 16
Number of Participants With Achievement of Psoriatic Arthritis Response Criteria (PsARC)
The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender joint count, swollen joint count, Physician Global Assessment of PsA, and Participant Global Assessment of Disease Activity. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement in each of the measures is defined below: 1) Decrease of ≥ 30% in tender joint counts; 2) Decrease of ≥ 30% in swollen joint counts; 3) Decrease of ≥ 20% in Physician Global Assessment of PsA; 4) Decrease of ≥ 20% in Participant's Global Assessment of Disease Activity
Time frame: Weeks 2, 4, 8, 12, 16
Number of Participants Meeting Achievement of Improvement of Bath Ankylosing Spondylitis Disease Activity (BASDAI) Score
BASDAI consists of a 0 to 10 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: 1) Fatigue (medical); 2) Spinal pain; 3) Joint pain and swelling; 4) Areas of localized tenderness; 5) Morning stiffness duration; 6) Morning stiffness severity. A higher count indicates worse disease. Each individual question response is scaled to a 0-10 score by dividing by 10, and the BASDAI is derived using the following formula: BASDAI = ((Q1 + Q2 + Q3 + Q4) + ((Q5 + Q6) / 2)) / 5
Time frame: Weeks 2, 4, 8, 12, 16
Change From Baseline in The Work Productivity and Activity Impairment (WPAI) at Week 16
The WPAI is a 6-item questionnaire that includes 2 visual analog scales: 1 for impact of disease on work and 1 for impact of disease on other daily activities. The WPAI also assesses absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity (overall work impairment/absenteeism plus presenteeism), and activity impairment. These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Time frame: Baseline, Week 16
Change From Baseline in the European Quality of Life 5D-5L (EQ-5D-5L) Utility Scores and Its Subcomponents
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. Change from Baseline in 5-level EuroQol 5-dimension (EQ-5D-5L) Utility Scores. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Time frame: Baseline, Weeks 4, 16
Change From Baseline in Patient-Reported Outcome Measures Information System (PROMIS)
The Patient-Reported Outcome Measures Information System Sleep Disturbance Short Form 8b assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. The items are evaluated on a 5-point Likert scale ranging from 1 = "not at all" to 5 = "very much" with a 7-day recall period. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
Time frame: Baseline, Weeks 4, 12, 16
| Milestone | Deucravacitinib | Placebo | Apremilast |
|---|---|---|---|
| Started | 312 | 312 | 105 |
| Completed | 312 | 311 | 105 |
| Not completed | 0 | 1 | 0 |
| Milestone | Deucravacitinib | Placebo | Apremilast |
|---|---|---|---|
| Started | 312 | 311 | 105 |
| Completed | 292 | 292 | 90 |
| Not completed | 20 | 19 | 15 |
| Withdrew: Lack of efficacy | 1 | 3 | 0 |
| Withdrew: Adverse event | 6 | 4 | 10 |
| Withdrew: Participant request to discontinue study treatment | 2 | 4 | 2 |
| Withdrew: Withdrawal by subject | 6 | 8 | 3 |
| Withdrew: Administrative reason by sponsor | 3 | 0 | 0 |
| Withdrew: Other reasons | 2 | 0 | 0 |
| Milestone | Deucravacitinib | Placebo | Apremilast |
|---|---|---|---|
| Started | 292 | 292 | 90 |
| Participants switched to deucravacitinib | 0 | 292 | 0 |
| Completed | 266 | 269 | 79 |
| Not completed | 26 | 23 | 11 |
| Withdrew: Lack of efficacy | 6 | 6 | 1 |
| Withdrew: Adverse event | 9 | 7 | 3 |
| Withdrew: Participant request to discontinue study treatment | 3 | 3 | 4 |
| Withdrew: Withdrawal by subject | 5 | 5 | 2 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 |
| Withdrew: Other reasons | 1 | 1 | 1 |
The American College of Rheumatology (ACR) 20 is defined as 20% improvement over baseline in tender (68) and swollen (66) joint counts and a 20% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16 | 169 | 123 |
DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.
| score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16 | -1.3133 ± 1.17420 | -0.9095 ± 1.10470 |
HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.
| score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Change From Baseline in Health Assessment Quiestionnaire - Disability Index (HAQ-DI) at Week 16 | -0.3103 ± 0.46159 | -0.2219 ± 0.46858 |
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Number of Participants Meeting Psoriasis Area and Severity Index 75 (PASI 75) at Week 16 | 63 | 23 |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Change From Baseline in the 36-item Short Form (SF-36) Physical Component Summary (PCS) Score at Week 16 | 6.194 ± 7.4640 | 4.262 ± 7.0328 |
Number of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Number of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16 | 74 | 66 |
Number participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count ≤ 1 2. Swollen joint count ≤ 1 3. Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain ≤ 15 5. Patient Global Assessment of PsA disease activity ≤ 20 6. HAQ-DI ≤ 0.5 7. Tender enthesial points ≤ 1
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Number of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16 | 80 | 46 |
FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16 | 2.6 ± 8.17 | 1.9 ± 8.54 |
Number of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count ≥ 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Number of Participants Meeting Dactylitis Resolution at Week 16 | 43 | 36 |
The American College of Rheumatology (ACR) 50 is defined as 50% improvement over baseline in tender (68) and swollen (66) joint counts and a 50% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Number of Participants Meeting American College of Rheumatology (ACR) 50 at Week 16 | 90 | 51 |
The American College of Rheumatology (ACR) 70 is defined as 70% improvement over baseline in tender (68) and swollen (66) joint counts and a 70% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Number of Participants Meeting American College of Rheumatology (ACR) 70 at Week 16 | 33 | 17 |
HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.
| score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Week 2 | -0.0546 ± 0.38637 | -0.1335 ± 0.34583 |
| Week 4 | -0.1547 ± 0.41308 | -0.1760 ± 0.40042 |
| Week 8 | -0.2301 ± 0.44365 | -0.1964 ± 0.43603 |
| Week 12 | -0.2544 ± 0.45565 | -0.2236 ± 0.46098 |
| Week 16 | -0.3103 ± 0.46159 | -0.2219 ± 0.46858 |
Number of participants who achieve a clinically meaningful improvement (≥ 0.35 improvement from baseline) in HAQ-DI score among participants with a HAQ-DI score ≥ 0.35 at baseline. HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Number of Participants Who Achieve a Clinically Meaningful Improvement in HAQ-DI Score at Week 16 | 131 | 118 |
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 | 14 | 10 |
| Week 8 | 26 | 19 |
| Week 12 | 45 | 22 |
| Week 16 | 63 | 23 |
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 | 4 | 3 |
| Week 8 | 10 | 7 |
| Week 12 | 31 | 15 |
| Week 16 | 41 | 13 |
PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value. Baseline is defined as the last measurement on or prior to date/time of first dose of study treatment.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 | 2 | 0 |
| Week 8 | 6 | 3 |
| Week 12 | 17 | 9 |
| Week 16 | 24 | 8 |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 | 3.364 ± 5.8439 | 2.771 ± 5.8897 |
| Week 12 | 5.419 ± 7.1066 | 3.578 ± 6.7537 |
| Week 16 | 6.194 ± 7.4640 | 4.262 ± 7.0328 |
Number of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 | 45 | 55 |
| Week 8 | 70 | 54 |
| Week 12 | 74 | 58 |
| Week 16 | 74 | 66 |
Number of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by SPARCC. The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (right \[R\]/left \[L\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 | 53 | 55 |
| Week 8 | 73 | 55 |
| Week 12 | 75 | 66 |
| Week 16 | 86 | 75 |
Number participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count ≤ 1 2. Swollen joint count ≤ 1 3. Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain ≤ 15 5. Patient Global Assessment of PsA disease activity ≤ 20 6. HAQ-DI ≤ 0.5 7. Tender enthesial points ≤ 1
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 | 19 | 16 |
| Week 8 | 35 | 28 |
| Week 12 | 56 | 24 |
| Week 16 | 80 | 46 |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. The MCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 MCS indicates an improvement.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 | 0.195 ± 7.7026 | 0.300 ± 7.7067 |
| Week 12 | 1.245 ± 8.6442 | 0.123 ± 9.1804 |
| Week 16 | 1.009 ± 9.7740 | -0.438 ± 9.3388 |
FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Week 2 | 0.8 ± 6.60 | 1.5 ± 6.52 |
| Week 4 | 1.3 ± 6.70 | 1.6 ± 6.95 |
| Week 8 | 2.9 ± 7.53 | 1.9 ± 8.54 |
| Week 12 | 2.2 ± 8.40 | 2.0 ± 8.91 |
| Week 16 | 2.6 ± 8.17 | 1.9 ± 8.54 |
Number of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count ≥ 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 | 24 | 30 |
| Week 8 | 31 | 27 |
| Week 12 | 39 | 29 |
| Week 16 | 43 | 36 |
The Psoriatic Arthritis Impact of Disease (PsAID) is a 12-item self-report that measures PsA symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale with a 1-week recall period. The PsAID has a total score, with a higher value indicating worse health. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in PsAID indicates an improvement.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Week 2 | -0.658 ± 1.3895 | -0.590 ± 1.2369 |
| Week 4 | -0.986 ± 1.5902 | -0.761 ± 1.5206 |
| Week 8 | -1.419 ± 1.7445 | -0.849 ± 1.8018 |
| Week 12 | -1.511 ± 1.9314 | -0.937 ± 1.9126 |
| Week 16 | -1.729 ± 2.0150 | -0.968 ± 1.9075 |
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAPSA indicates an improvement.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Week 2 | -4.9619 ± 12.27319 | -5.9569 ± 12.24097 |
| Week 4 | -9.0129 ± 11.93271 | -8.2813 ± 12.79788 |
| Week 8 | -13.5855 ± 14.33402 | -10.7292 ± 16.10715 |
| Week 12 | -15.7385 ± 16.02197 | -11.8980 ± 16.33187 |
| Week 16 | -17.5225 ± 16.66002 | -12.1547 ± 17.74566 |
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 2 | 25 | 18 |
| Week 4 | 44 | 42 |
| Week 8 | 69 | 55 |
| Week 12 | 95 | 66 |
| Week 16 | 104 | 78 |
The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 2 | 1 | 1 |
| Week 4 | 2 | 1 |
| Week 8 | 12 | 4 |
| Week 12 | 20 | 8 |
| Week 16 | 30 | 9 |
The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 | 10 | 10 |
| Week 8 | 13 | 13 |
| Week 12 | 16 | 11 |
| Week 16 | 17 | 15 |
The DAS28-CRP is a composite outcome measure that assesses: 1) How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; 2) CRP in the blood to measure the degree of inflammation; 3) Participant Global Assessment of Disease Activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission, 2.6 to 3.2: Low disease activity, 3.2 to 5.1: Moderate disease activity, \> 5.1: High disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Week 2 | -0.3226 ± 0.74392 | -0.4044 ± 0.70334 |
| Week 4 | -0.6292 ± 0.84069 | -0.5888 ± 0.75652 |
| Week 8 | -0.9992 ± 1.01750 | -0.7579 ± 0.99991 |
| Week 12 | -1.1279 ± 1.14379 | -0.8826 ± 1.03604 |
| Week 16 | -1.3133 ± 1.17420 | -0.9095 ± 1.10470 |
The DAS28-CRP is a composite outcome measure that assesses: 1) How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; 2) CRP in the blood to measure the degree of inflammation; 3) Participant Global Assessment of Disease Activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission, 2.6 to 3.2: Low disease activity, 3.2 to 5.1: Moderate disease activity, \> 5.1: High disease activity.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 2 | 23 | 19 |
| Week 4 | 39 | 31 |
| Week 8 | 35 | 32 |
| Week 12 | 54 | 39 |
| Week 16 | 56 | 43 |
The DAS28-CRP is a composite outcome measure that assesses: 1) How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; 2) CRP in the blood to measure the degree of inflammation; 3) Participant Global Assessment of Disease Activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission, 2.6 to 3.2: Low disease activity, 3.2 to 5.1: Moderate disease activity, \> 5.1: High disease activity.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 2 | 13 | 7 |
| Week 4 | 27 | 14 |
| Week 8 | 57 | 31 |
| Week 12 | 64 | 35 |
| Week 16 | 84 | 44 |
The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite measure calculated from the Physician Global Assessment of PsA, the Participant Global Assessment of Disease Activity, the Short Form-36 PCS, the swollen joint count, the tender joint count, the Enthesitis (LEI), the Dactylitis (LDI) (Basic), and the High-sensitivity C-reactive protein (hsCRP). The range of PASDAS is 0-10. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 | -0.8037 ± 0.90993 | -0.7690 ± 0.90884 |
| Week 12 | -1.5273 ± 1.27441 | -1.0137 ± 1.17400 |
| Week 16 | -1.7047 ± 1.32902 | -1.1434 ± 1.26434 |
Four domains are used to calculate the modified Composite Psoriatic Disease Activity Index (mCPDAI): joints (66 swollen joint count and 68 tender joint count; Health Assessment Questionnaire), skin (PASI and DLQI), dactylitis (a simple count of each digit involved), and enthesitis (number of tendons/fascia insertion sites showing enthesitis scored from 0 to 4, based on palpation of Achilles tendon and bilateral plantar fasciae insertion). The mCPDAI is scored using a 4 point scale from 0 (no disease activity) to 3 (most severe disease activity), giving an mCPDAI score range of 0 through 12. A higher score indicates more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 | -0.8 ± 1.57 | -0.7 ± 1.76 |
| Week 8 | -1.3 ± 1.71 | -0.9 ± 1.86 |
| Week 12 | -1.6 ± 1.80 | -1.0 ± 1.87 |
| Week 16 | -1.8 ± 1.97 | -1.2 ± 2.02 |
The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender joint count, swollen joint count, Physician Global Assessment of PsA, and Participant Global Assessment of Disease Activity. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement in each of the measures is defined below: 1) Decrease of ≥ 30% in tender joint counts; 2) Decrease of ≥ 30% in swollen joint counts; 3) Decrease of ≥ 20% in Physician Global Assessment of PsA; 4) Decrease of ≥ 20% in Participant's Global Assessment of Disease Activity
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 2 | 71 | 69 |
| Week 4 | 128 | 98 |
| Week 8 | 163 | 126 |
| Week 12 | 176 | 122 |
| Week 16 | 187 | 138 |
BASDAI consists of a 0 to 10 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: 1) Fatigue (medical); 2) Spinal pain; 3) Joint pain and swelling; 4) Areas of localized tenderness; 5) Morning stiffness duration; 6) Morning stiffness severity. A higher count indicates worse disease. Each individual question response is scaled to a 0-10 score by dividing by 10, and the BASDAI is derived using the following formula: BASDAI = ((Q1 + Q2 + Q3 + Q4) + ((Q5 + Q6) / 2)) / 5
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Week 2 | 2 | 1 |
| Week 4 | 6 | 1 |
| Week 8 | 12 | 5 |
| Week 12 | 11 | 4 |
| Week 16 | 17 | 4 |
The WPAI is a 6-item questionnaire that includes 2 visual analog scales: 1 for impact of disease on work and 1 for impact of disease on other daily activities. The WPAI also assesses absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity (overall work impairment/absenteeism plus presenteeism), and activity impairment. These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Absenteeism | -0.59 ± 21.406 | 1.56 ± 22.108 |
| Presenteeism | -13.97 ± 23.380 | -5.96 ± 22.238 |
| Work Productivity | -13.71 ± 24.087 | -5.79 ± 23.951 |
| Activity Impairment | -15.72 ± 25.226 | -8.16 ± 24.178 |
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. Change from Baseline in 5-level EuroQol 5-dimension (EQ-5D-5L) Utility Scores. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 Utility Score | 0.0505 ± 0.17658 | 0.0655 ± 0.19080 |
| Week 16 Utility Score | 0.0990 ± 0.21113 | 0.0770 ± 0.22126 |
| Week 4 Mobility | -0.2 ± 0.74 | -0.2 ± 0.76 |
| Week 16 Mobility | -0.3 ± 0.92 | -0.3 ± 0.87 |
| Week 4 Self-Care | -0.1 ± 0.73 | -0.2 ± 0.71 |
| Week 16 Self-Care | -0.2 ± 0.83 | -0.2 ± 0.81 |
| Week 4 Usual Activities | -0.1 ± 0.76 | -0.2 ± 0.73 |
| Week 16 Usual Activities | -0.3 ± 0.84 | -0.3 ± 0.83 |
| Week 4 Pain/Discomfort | -0.3 ± 0.75 | -0.3 ± 0.80 |
| Week 16 Pain/Discomfort | -0.5 ± 0.89 | -0.4 ± 0.93 |
| Week 4 Anxiety/Depression | -0.1 ± 0.76 | -0.1 ± 0.78 |
| Week 16 Anxiety/Depression | -0.1 ± 0.77 | 0.0 ± 0.88 |
The Patient-Reported Outcome Measures Information System Sleep Disturbance Short Form 8b assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. The items are evaluated on a 5-point Likert scale ranging from 1 = "not at all" to 5 = "very much" with a 7-day recall period. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.
| Score on a scale | Deucravacitinib | Placebo |
|---|---|---|
| Week 4 | -1.35 ± 6.958 | -1.41 ± 6.156 |
| Week 12 | -1.76 ± 7.945 | -1.48 ± 7.145 |
| Week 16 | -2.21 ± 7.447 | -1.53 ± 7.134 |
Collected over All-cause mortality was assessed for all participants from date of randomization to their study completion (up to approximately 30 months). SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 30 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Deucravacitinib-Controlled | 0/312 (0%) | 6/312 (1.9%) | 89/312 (28.5%) |
| Placebo-Controlled | 1/312 (0.3%) | 3/311 (1%) | 93/311 (29.9%) |
| Apremilast-Controlled | 0/105 (0%) | 4/105 (3.8%) | 39/105 (37.1%) |
| Deucravacitinib-Active Treatment | 0/292 (0%) | 12/292 (4.1%) | 90/292 (30.8%) |
| Placebo-Active Treatment | 1/292 (0.3%) | 13/292 (4.5%) | 106/292 (36.3%) |
| Apremilast-Active Treatment | 0/90 (0%) | 6/90 (6.7%) | 32/90 (35.6%) |
| Deucravacitinib-Open Label Extension | 0/245 (0%) | 16/245 (6.5%) | 58/245 (23.7%) |
| Placebo-Open Label Extension | 1/254 (0.4%) | 13/254 (5.1%) | 61/254 (24%) |
| Apremilast-Open Label Extension | 0/70 (0%) | 6/70 (8.6%) | 23/70 (32.9%) |
| Event | Deucravacitinib-Controlled | Placebo-Controlled | Apremilast-Controlled | Deucravacitinib-Active Treatment | Placebo-Active Treatment | Apremilast-Active Treatment | Deucravacitinib-Open Label Extension | Placebo-Open Label Extension | Apremilast-Open Label Extension |
|---|---|---|---|---|---|---|---|---|---|
| Atrioventricular block second degreeCardiac disorders | 0/312 | 0/311 | 0/105 | 0/292 | 0/292 | 0/90 | 0/245 | 0/254 | 1/70 |
| Rhegmatogenous retinal detachmentEye disorders | 0/312 | 0/311 | 0/105 | 0/292 | 0/292 | 0/90 | 0/245 | 0/254 | 1/70 |
| PneumoniaInfections and infestations | 2/312 | 0/311 | 0/105 | 0/292 | 2/292 | 0/90 | 0/245 | 1/254 | 1/70 |
| Vestibular neuronitisInfections and infestations | 0/312 | 0/311 | 0/105 | 0/292 | 0/292 | 0/90 | 0/245 | 0/254 | 1/70 |
| Limb injuryInjury, poisoning and procedural complications | 1/312 | 0/311 | 0/105 | 0/292 | 0/292 | 0/90 | 0/245 | 0/254 | 1/70 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/312 | 0/311 | 0/105 | 0/292 | 1/292 | 1/90 | 1/245 | 0/254 | 1/70 |
| Acute myocardial infarctionCardiac disorders | 0/312 | 0/311 | 0/105 | 0/292 | 1/292 | 1/90 | 1/245 | 0/254 | 0/70 |
| Inguinal herniaGastrointestinal disorders | 0/312 | 0/311 | 0/105 | 0/292 | 0/292 | 1/90 | 0/245 | 0/254 | 0/70 |
| Urinary tract infectionInfections and infestations | 0/312 | 0/311 | 0/105 | 0/292 | 0/292 | 1/90 | 0/245 | 0/254 | 0/70 |
| SpondylolisthesisMusculoskeletal and connective tissue disorders | 0/312 | 0/311 | 0/105 | 0/292 | 0/292 | 1/90 | 0/245 | 0/254 | 0/70 |
| Event | Deucravacitinib-Controlled | Placebo-Controlled | Apremilast-Controlled | Deucravacitinib-Active Treatment | Placebo-Active Treatment | Apremilast-Active Treatment | Deucravacitinib-Open Label Extension | Placebo-Open Label Extension | Apremilast-Open Label Extension |
|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 19/312 | 13/311 | 4/105 | 27/292 | 28/292 | 8/90 | 27/245 | 16/254 | 13/70 |
| NasopharyngitisInfections and infestations | 14/312 | 21/311 | 4/105 | 27/292 | 36/292 | 4/90 | 14/245 | 13/254 | 5/70 |
| DiarrhoeaGastrointestinal disorders | 11/312 | 15/311 | 11/105 | 10/292 | 6/292 | 11/90 | 2/245 | 5/254 | 3/70 |
| COVID-19Infections and infestations | 22/312 | 17/311 | 7/105 | 19/292 | 30/292 | 8/90 | 13/245 | 21/254 | 0/70 |
| HeadacheNervous system disorders | 13/312 | 11/311 | 8/105 | 4/292 | 4/292 | 5/90 | 2/245 | 3/254 | 0/70 |
| NauseaGastrointestinal disorders | 7/312 | 6/311 | 7/105 | 5/292 | 8/292 | 2/90 | 3/245 | 2/254 | 0/70 |
| HypertensionVascular disorders | 8/312 | 8/311 | 7/105 | 7/292 | 8/292 | 0/90 | 2/245 | 7/254 | 2/70 |
| Urinary tract infectionInfections and infestations | 3/312 | 3/311 | 2/105 | 8/292 | 5/292 | 5/90 | 1/245 | 2/254 | 2/70 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 5/312 | 10/311 | 2/105 | 5/292 | 13/292 | 5/90 | 8/245 | 6/254 | 2/70 |
| Age, Continuous(Years) | Deucravacitinib | Placebo | Apremilast | Total |
|---|---|---|---|---|
| Mean | 48.7 ± 11.73 | 49.3 ± 12.18 | 49.1 ± 13.47 | 49.0 ± 12.17 |
| Sex: Female, Male(Participants) | Deucravacitinib | Placebo | Apremilast | Total |
|---|---|---|---|---|
| Female | 153 | 168 | 56 | 377 |
| Male | 159 | 144 | 49 | 352 |
| Ethnicity (NIH/OMB)(Participants) | Deucravacitinib | Placebo | Apremilast | Total |
|---|---|---|---|---|
| Hispanic or Latino | 54 | 50 | 16 | 120 |
| Not Hispanic or Latino | 195 | 200 | 64 | 459 |
| Unknown or Not Reported | 63 | 62 | 25 | 150 |
| Race (NIH/OMB)(Participants) | Deucravacitinib | Placebo | Apremilast | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 13 | 7 | 4 | 24 |
| Asian | 54 | 45 | 28 | 127 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 223 | 240 | 65 | 528 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 22 | 19 | 8 | 49 |
Showing the first 100 of 138 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Jul 2021 to primary completion in Nov 2024, 39 months.
Results were first posted in Apr 2025, 5 months after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 39 months is above that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib